AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00152854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 1g po qid
Study NCT04138966 — intervention group
Intervention type: DEVICE
Intervention: Skin Conductance
Description: Measures skin conductance as a surrogate to nociception
Study NCT04705740 — intervention group
Intervention type: OTHER
Intervention: ERCP
Description: ERCPs performed annually by an endoscopist
Study NCT00152854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: acetaminophen 1g po qid for 7 days
Study NCT00152854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, sugar pill
Study NCT02573467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study NCT02133937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gantenerumab
Description: Single subcutaneous injection of a high concentration liquid formulation
Study NCT02573467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study NCT04361045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StriveWeekly
Description: The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning.
Study NCT04717180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia rehabilitation using software program or conventional therapy
Description: Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
Study NCT04250675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic leg compressions
Description: Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
Study NCT04250675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
Study NCT04040855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Multi-professional medication review
Study NCT00937911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT01495273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transtracheal injection
Description: Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
Study NCT02133937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gantenerumab
Description: Single subcutaneous injection of a lyophilized formulation
Study NCT01495273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transtracheal injection
Description: Control group will undergo transtracheal injection with a standard needle/syringe assembly.
Study NCT01144546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising (45 degree leg elevation for 1-2 min)
Description: the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
Study NCT03515798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
Study NCT03515798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant EC-paclitaxel chemotherapy
Description: The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
Study NCT03515798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant EC-paclitaxel chemotherapy
Description: The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
Study NCT04296292 — intervention group
Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
Study NCT02993159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimoxifene
Description: Applied to the breast
Study NCT02993159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02993159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02993159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT02993159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Applied to the breast
Study NCT02993159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT00811109 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Standard Hemodialysis
Description: Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
Study NCT00811109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: with Blood Volume Management (BVM®) only
Description: Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
Study NCT00811109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring
Description: Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
Study NCT01033227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite injection, usp
Description: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
Study NCT01901588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
Study NCT01901588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intraoperative dose of intravenous placebo
Study NCT01975480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Study NCT02011464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel is infiltrated into posterior compartment for pain control
Study NCT02011464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is infiltrated into posterior compartment for control
Study NCT04834115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: Oral ivermectin at a one time dose
Study NCT04834115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo at a one time dose
Study NCT03612700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPFA-rich foods
Description: Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
Study NCT01390935 — intervention group
Intervention type: OTHER
Intervention: guideline adherence
Description: guideline adherence of physician
Study NCT04034680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME
Description: The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
Study NCT04034680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-only intervention
Description: Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
Study NCT01960842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Description: Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Study NCT01960842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT01960842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT01960842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study NCT02021604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
Study NCT03161847 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study NCT02528136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Study NCT02528136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT03648970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: The participant will be given pravastatin 2 x 20 mg per oral daily
Study NCT03662971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
Study NCT02396797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The new atWork intervention
Description: atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting.
Study NCT02396797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The original atWork intervention
Description: This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
Study NCT00578058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy
Study NCT01158404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900009 - Dose Escalation Phase (Part A)
Description: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
Study NCT01158404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900009 - Dose Confirmation Phase (Part B)
Description: 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
Study NCT04772430 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: snow globe
Description: Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
Study NCT01160744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6)
Description: Day 1 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (AUC 6)
Description: Day 1 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² on Days 1 and 8 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² on Days 1 and 8 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (AUC 5)
Description: Day 1 of every 21-day cycle
Study NCT01160744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5)
Description: Day 1 of every 21-day cycle
Study NCT01535066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Receive acupuncture
Study NCT01535066 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Receive sham acupuncture
Study NCT04279678 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve repair
Description: surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
Study NCT02227966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02227966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Yband (YDT-201N)
Description: tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
Study NCT00726427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose escalation to achieve maximum tolerated dose
Study NCT00726427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral single dose
Study NCT01060111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Standard
Description: Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
Study NCT01060111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Slow
Description: Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
Study NCT01060111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol booster
Description: Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
Study NCT01004393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
Study NCT01997255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
Study NCT02965131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary portocaval shunt
Description: The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
Study NCT04784403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 PCR and serology tests
Description: Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
Study NCT04643431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perflutren
Description: The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
Study NCT03646188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
Study NCT03646188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
Study NCT03646188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
Study NCT03646188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.